BIBLIOGRAPHIE

1. Hormones. E-E Baulieu and Paul A.Kelly. Hermann publishers1990)

2. Twenty-four hours mean plasma testosterone concentration decline in non premenopausal women. Zumoff B, Strain GW,Miller LK, Rosner W. J Clin Endocrinol Metab, 1995, 80:1429-1430

3. Consequences of oral contraceptive troubles with decrease of androgen ovarian synthesis. Harrison’s Principes de medicine interne – 331 : Maladies de l’ovaire et de l’appareil génital féminin: p. 1832-1833, 1988.

3.1.  Effects of oral contraceptives on breast epithelial proliferation. Isaksson E, von Schoultz E, Odlind V, Soderqvist G, Csemiczky G, Carlstrom K, Skoog L, von Schoultz B. Department of Oncology, Radiumhemmet, Karolinska Hospital, Stockholm, Sweden Breast Cancer Res Treat2001 Jan; 65(2):163-169

3.2  Oral contraceptive use as a risk factor for premenopausal breast cancer: a meta-analysis.

Kahlenborn C, Modugno F, Potter DM, Severs WB. Mayo Clin Proc. 2006 Oct;81(10):1290-302.

3.3. Effect of Depo-Medroxyprogesterone Acetate on Breast Cancer Risk among Women 20 to 44 Years of Age. Christopher I. Li, Elisabeth F. Beaber, Mei Tzu Chen Tang,Peggy L. Porter, Janet R.Daling,  Kathleen E. Malone. Cancer Res; 72(8); 2028–35.2012

4.  Impact of Oral Contraceptives on Sex Hormone-Binding Globulin and Androgen Levels: A Retrospective Study in Women with Sexual Dysfunction.Panzer et al. The Journal of Sexual Medicine, January 2006;3:p.104-113

5. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J; Writing Group for the Women's Health Initiative Investigators. JAMA. 2002 Jul 17;288(3):321-33.

6. Promotional tone in reviews of menopausal hormone therapy after the Women's Health Initiative: an analysis of published articles. Fugh-Berman A, McDonald CP, Bell AM, Bethards EC, Scialli AR.Department of Physiology and Biophysics, Georgetown University Medical Center, Washington, DC, USA.PLoS Med. 2011 Mar;8(3):e1000425. Epub 2011 Mar 15.

7. Androgens and osteocalcin during the menstrual cycle. Massafra C, De Felice C, Agnusdei DP, Gioia D, Bagnoli F. Department of Obstetrics and Gynecology, University of Siena, Italy. J Clin Endocrinol Metab. 1999 Mar;84(3):971-4

8.Testosterone measured by 10 immunoassays and by isotope-dilution gas chromatography-mass spec­trometry in sera from 116 men,women, and children. Taieb J, Mathian B, Millot F, Patricot MC, Mathieu E, Queyrel N, Lacroix I, Somma-Delpero C, Boudou P. Hormonology Laboratory, A. Béclère Hospital, 92141 Clamart, France. Clinical Chemistry 49, 1381-1395, 2003.

9. Androgen levels in adult females: changes with age, menopause, and oophorectorny. Davison SL, Bell R, Donath S, Montalto JG, Davis SR. J Clin Endocrinol Metab, 2005, 90:3847-53.

10. Androgen glucuronides, instead of testosterone, as the new markers of androgenic activity in women.Labrie F, Bélanger A, Bélanger R Bérubé R, Martel C, Cusan L, Gomez J, Candas B, Castiel I, Chaussade V, Deloche C, Leclaire J.. J Steroid Biochem Mol Biol, 2006, 99:182-188.

11. Wide distribution of the serum dehydroepiandrosterone and sex steroid levels in postmenopausal women: role of the ovary? Labrie F, Martel C, Balser J.  Endoceutics Inc, Quebec City, Quebec, Canada. Menopause.2011 Jan: 18 (1):30-43.

12. Low testosterone levels predict all-cause mortality and cardiovascular events in women: a prospective cohort study in German primary care patients. Sievers C, Klotsche J, Pieper L, Schneider HJ, März W, Wittchen HU, Stalla GK, Mantzoros C.Department of Endocrinology, Max Planck Institute of Psychiatry, Kraepelinstrasse 2-10, Munich, Germany. Eur J Endocrinol. 2010 Oct;163(4):699-708. Epub 2010 Aug 4.

13. Higher serum free testosterone concentration in older women is associated with greater bone mineral density, lean body mass, and total fat mass: the cardiovascular health study. Rariy CM, Ratcliffe SJ, Weinstein R, Bhasin S, Blackman MR, Cauley JA, Robbins J, Zmuda JM, Harris TB, Cappola AR. Division of Endocrinology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA. J Clin Endocrinol Metab. 2011 Apr;96(4):989-96. Epub 2011 Feb 2.

14.Hormonal Influences Upon Connective Tissue Changes of Aging, SOBEL H. and MARMORSTON J. Institute for Medical Research, Cedars of Lebanon Hospital, and the Depart-ment of
Biochemistry and Nutrition and the Department of Medicine, University of Southern
California, Los Angeles, California,in: PINCUS G (ed. ) Recent Progress in Hormone Research, vol. 14. Academic New York 1958.

15. Brain levels of sex steroid hormones in men and women during normal aging and in Alzheimer's disease. Rosario ER, Chang L, Head EH, Stanczyk FZ, Pike CJ. Davis School of Gerontology, University of Southern California, Los Angeles, CA 90089, USA. Neurobiol Aging. 2011 Apr;32(4):604-13. Epub 2009 May 9.

16. La pathologie obstructive congénitale de l’uretère terminal. G. Debled : p. 446- 452 ; Acta Urologica Belgica, 1971, 39, 371-465) See pathology in : http://www.hmseurope.com/Pathologie uretère terminal.pdf uretère terminal.pdf 

17. High Court Rejects Pfizer Hormone Therapy Lawsuit Appeal

Date Published: Wednesday, June 22nd, 2011

The U.S. Supreme Court refused to hear a Pfizer Inc. unit’s appeal of a $58 million award in a case against Premarin and Prempro menopause drugs.

Three Nevada women who contracted breast cancer after taking the company’s menopause drugs were awarded the amount in a 2007 case.

The rebuff leaves the amount as the largest to be upheld on appeal in thousands of hormone replacement drug suits. Over six million women took Prempro and other menopause drugs before a 2002 study pointed out their links to cancer. At one point Pfizer and his units faced more than 10,000 claims, according to lawyers for former users.

The Nevada Supreme Court concluded jurors properly held Pfizer’s Wyeth unit responsible for hiding the breast-cancer risks of Premarin and Prempro. The original 2007 case resulted in an award totaling $134.1 million to Arlene Rowatt, Jeraldine Scofield and Pamela Forrester. The trial judge later reduced the verdict to $57.6 million.

Yearly sales of Wyeth’s hormone‐replacement drugs exceeded $2 billion before a 2002 study,

sponsored by the U.S. National Institutes of Health, suggested that women using the medicines had a 24 percent higher risk of breast cancer.

Pfizer, the world’s largest drug maker, acquired Wyeth in 2009 settled a third of the pending cases over its Prempro menopause drug. The company said last month that it set aside $772 million to resolve claims over the medicine.

18. DEBLED G.  The menopause disease. Approaches to aging control : 19:17-24,October 2015